Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of image-guided radiotherapy plus Panitumumab in muscle-invasive bladder cancer
2009-018246-38Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- May 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in transitional cell carcinoma (TCC) and Bladder cancer in situ (CIS), sponsored by Netherlands Cancer Institute. Primary endpoint: Acute toxicity rate during radiotherapy with Panitumumab. Started May 2010; status: active.
02
Drugs
panitumumab
03
Conditions
transitional cell carcinoma (TCC)Bladder cancer in situ (CIS)
Beyond the preview
Go deeper on 2009-018246-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018246-38.